Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Collaboration Revenue: Collaboration revenue was zero for the three months ended September 30, 2024, as compared to $0.8 million for the three months ended September 30, 2023. The decrease of $0.8 ...

To pave the way for the launch of Oxbryta, Pfizer’s GBT unit approached Riester Rx to conduct research and develop a market-shaping campaign to increase awareness of sickle cell disease.

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...

It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than standard plerixafor.

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

Called Casgevy, the gene-editing treatment is for people with sickle cell disease and a related blood disorder called beta thalassemia. UK regulators approved the treatment in November 2023 ...

The 43-year-old had diagnoses of sickle cell disease, epilepsy and delusional disorder, and a jury found that he died of acute chest syndrome – the most common fatal complication of sickle cell ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.